Cohance Lifesciences Limited — Board Meeting, 13-08-2025: Outcome of Board Meeting

Cohance Lifesciences' Board has approved the financial results for the quarter ended June 30, 2025. Consolidated revenue hit ₹549.3 Cr, up 13% year-on-year, or over 25% excluding inventory destocking in Pharma CDMO. Gross margins expanded to 73%. Adjusted EBITDA stood at ₹131.4 Cr, with a 23.9% margin, reflecting strategic investments.

Niche technologies now comprise over 20% of sales. The company appointed Yann D’Hervé as CEO of its CDMO business and formed an External Advisory Board. Significant orders, USFDA approvals for a partner's program, and facility expansions are on track, boosting growth pillars.